SPATIAL OMICS MARKET ANALYSIS

Omics is a term brief for various diverse studies which includes genomics, transcriptomics, proteomics and metabolomics. The traditional transcriptomics and proteomics approaches have provided insight into disease progression by identifying discrete cellular subpopulation or micro environmental signatures characteristics of normal or pathological tissues. The spatial pattern of the genome have been identified for the treatment of various diseases because of that spatial information is being used as a diagnostic biomarker for identifying the medical condition. Special omics combines molecular analysis with spatial information on the cells localization within the tissue. Thus, this technology is providing a powerful tool to understand important mechanisms such as tissue organisation or cell regulation.

Global spatial omics market is estimated to be valued at USD 315.5 Mn in 2024 and is expected to exhibit a CAGR of 9.4% during the forecast period (2024-2031).

Figure 1. Global Spatial Omics Market Value (US$ Mn), By Regional Insights, 2024

To learn more about this report, request a free sample copy

Increasing cancer population worldwide is expected to drive growth of the global spatial omics market over the forecast period.

For instance, according to World Health Organisation, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. There were 1.41 million cases of prostate cancer worldwide.

Figure 2. Global Spatial Omics Market Share (%), By Product Type, 2024

To learn more about this report, request a free sample copy

The increasing product launches and approvals are expected to drive the market growth over the forecast period.

For instance, in August 2021, vizgen, the life science company dedicated to improving human health by visualizing single cell spatial genomics information has commercialized MERSCOPE platform, MERSCOPE is the only platform for MERFISH technology. MERFISH provides the highest detection efficacy available for spatially profiling gene expression across whole tissues and resolving individual transcripts with nanometre scale resolution through combinatorial labelling, sequential imaging, and error robust barcoding.

Moreover, in March 2021, Veranome Biosystems LLC, has revealed the world first complete sample to insight high plex spatial omics solution for single cell level characterization. The Pisces technology has been demonstrated to map thousands of custom gene panels in tissues at sub cellular resolution with high gene counts per cell and high sensitivity.

Recent Developments

In November 2023, Stellaromics, a premier provider of in situ spatial multi-omics technology, announced the successful completion of its Series A funding round, securing US$ 25 million. This funding round saw participation from Plaisance Capital Management and a prominent Silicon Valley-based private family office, highlighting strong investor confidence in the company's innovative approach to spatial multi-omics technology.

In June 2023, OWKIN and 10x Genomics, Inc., a leading techbio company, announced that it had signed a deal to integrate 10x Genomics spatial omics and single-cell technologies into the ambitious MOSAIC project. This project has garnered acclaim for its pioneering efforts in tumor analysis aimed at advancing therapeutic discovery.

In December 2021, Rebus Biosystems, Inc., a life science technology company, revealed its acquisition of EEL Transcriptomics AB's intellectual property and associated assay assets. EEL Transcriptomics AB, a privately held enterprise specializing in high-plex spatial transcriptomics with single-cell resolution, has been the focus of this acquisition. The specific terms of the transaction have not been disclosed.

In March 2021, Rebus Biosystems, Inc. announced the launch of the Rebus Esper spatial omics platform. This cutting-edge platform empowers researchers to delve deeper into tissue biology, facilitating advancements in various fields such as neurology, oncology, infectious diseases, and immunology.

Global Spatial Omics Market – Impact of Coronavirus (Covid-19) Pandemic

Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 193,657,725 cases and 4,154,660 deaths due to coronavirus disease (COVID-19) were reported till July 25, 2021, across the globe.

Covid-19 did have negative impact on spatial omics market in early days of covid-19 spread, with decline in the company’s revenue in the second quarter of 2020, due to widespread customer lab closures due to lockdown. However, the impact did not last longer and company’s revenue increased gradually due to increase in consumables revenue driven by growth in instrument installed base.

For instance, the revenue of 10x Genomics of the fourth quarter of 2020 was 112.2 million with 49% increase in the revenue which was 75.3 in the third quarter.

Global Spatial Omics Market Restraint

Spatial omics is relatively new area of research, the global development of spatial transcriptomics research has been concentrated in the U.S and other developed countries. Moreover limited research expertise is available in this field and lack of skilled professionals. 

Key Players

Major players operating in the global spatial omics market include 10x Genomics, Akoya Bioscience Inc., Biognosys AG, BioSpyder Technologies, Bio-Techne, Bruker, Brooks Automation Inc., Danaher Corporation, Diagenode Diagnostics, Fluidigm Corporation, IonPath Inc., Millennium Science Pty Ltd, NanoString Technologies, PerkinElmer, Rebus Biosystems, Ultivue Inc., Vizgen Corp, Dovetail Genomics, S2 Genomics, Inc., Seven Bridges Genomics.